Home Alzheimer’s Disease Abiraterone Acitate and Prednisome Plus Apalutamide Reduced Risk of Progression, Death for...

Abiraterone Acitate and Prednisome Plus Apalutamide Reduced Risk of Progression, Death for Patients with mCRPC

For patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT), abiraterone acetate (Zytiga) and prednisone plus the addition of apalutamide (Erleada) reduced the risk of radiographic progression or death by 30%, according to data presented during the 2021 Genitourinary Cancers Symposium.1

The final analysis from the phase 3 ACIS study showed that at a median follow-up of 54.8 months, the median radiographic progression-free survival (rPFS) was 24 months with the addition of apalutamide compared with 16.6 months with placebo plus abiraterone and prednisone (HR, 0.70). The data sustained the rPFS benefit with apalutamide observed at the primary efficacy analysis conducted at a median follow-up of 25.7 months: 22.6 months with apalutamide versus 16.6 months in the control arm (HR, 0.69; P <.0001).

The rPFS benefit…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments